U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Pegamotecan, a pegylated-camptothecin, is a topoisomerase-I inhibitor with a prolonged circulating half-life, tolerability, and passive tumor accumulation. Enzon Pharmaceutical used pegamotecan in trials for the treatment of cancer of the stomach, sarcoma, soft tissue, and gastroesophageal cancer. However, in 2005 Enzon Pharmaceuticals announced that it had discontinued further development of that drug. The Company's decision was based on an interim analysis of the data from a Phase 2b trial in patients with gastric or gastroesophageal cancers. Based on a strategic analysis of the potential investment return versus the required resource allocation and associated development risks, the Company decided not to pursue other potential indications for pegamotecan.

Originator

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
2009-01
Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
1998

Sample Use Guides

In Vivo Use Guide
treated with 7,000 mg/m(2) of pegamotecan as a 1-h infusion every 21 days until disease progression or unacceptable toxicity
Route of Administration: Intravenous
Name Type Language
PROTHECAN
Preferred Name English
PEGAMOTECAN
INN   USAN  
USAN   INN  
Official Name English
PEG-CAMPTOTHECIN
Common Name English
EZ-246
Code English
L-ALANINE, (4S)-4-ETHYL-3,4,12,14-TETRAHYDRO-3,14-DIOXO-1H-PYRANO(3',4':6,7)INDOLIZINO (1,2-B)QUINOLIN-4-YL ESTER, MONO(TRIFLUOROACETATE), REACTION PRODUCTS WITH POLYETHYLENE GLYCOL BIS (CARBOXYMETHYL) ETHER
Common Name English
PEGAMOTECAN [USAN]
Common Name English
pegamotecan [INN]
Common Name English
Code System Code Type Description
ChEMBL
CHEMBL2104977
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
FDA UNII
ZY7ZTE7LFH
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
SMS_ID
300000034263
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
EPA CompTox
DTXSID70206835
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
USAN
PP-81
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
INN
8508
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
CAS
581079-18-7
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
NCI_THESAURUS
C174957
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
DRUG BANK
DB12842
Created by admin on Mon Mar 31 23:09:05 GMT 2025 , Edited by admin on Mon Mar 31 23:09:05 GMT 2025
PRIMARY
Display Structure of PEGAMOTECAN
SUBSTANCE RECORD
PEGAMOTECAN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966